Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory Phase II Study of the Combination of a Tyrosine Kinase Inhibitor (STI571) and a Pegylated Human Recombinant Interferon alfa2b (PEGINTRON) in the Treatment of Chronic Myeloid Leukemia in Chronic Phase

NCT00511121 is registered in ClinicalTrials.gov with University of Bologna as lead sponsor.

NCT NCT00511121
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00511121 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory Phase II Study of the Combination of a Tyrosine Kinase Inhibitor (STI571) and a Pegylated Human Recombinant Interferon alfa2b (PEGINTRON) in the Treatment of Chronic Myeloid Leukemia in Chronic Phase
Lead sponsor
University of Bologna
Phase
Phase 2
Overall status
Terminated
Start date
April 30, 2001
Completion date
Not reported
Enrollment
5
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myeloid leukemia